SHP099

• UNSPSC Description:

  SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth[1][2].

• Target Antigen:

  Phosphatase; SHP2

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/SHP099.html

• Purity:

  99.80

• Solubility:

  DMSO : 12 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  NC1=NC(N2CCC(C)(N)CC2)=CN=C1C3=CC=CC(Cl)=C3Cl

• Molecular Weight:

  352.26

• References & Citations:

  [1]Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535(7610):148-52.|[2]Sun X, et al. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia. 2018 May;32(5):1246-1249.ACS Nano. 2023 Aug 14.|Acta Pharm Sin B. 11 August 2021.|Acta Pharm Sin B. 17 February 2022.|Acta Pharm Sin B. 2024 Mar 18.|Ann Transl Med. 2020 Dec;8(23):1570.|Biochem Biophys Res Commun. 2023 Jul 20.|Biochem Biophys Res Commun. 2024 Mar 26, 149812.|bioRxiv. 2019 Sep.|bioRxiv. 2024 Feb 5.|bioRxiv. 2024 November 06.|Br J Cancer. 2022 Dec 7.|Brain Pathol. 2020 Mar;30(2):373-385.|Cancer Cell Int. 2021 Jul 3;21(1):337.|Cancer Res Commun. August 17 2022.|Cancer Res. 2021 Apr 5;canres.3738.2020.|Cancers (Basel). 2022 May 12;14(10):2377.|Cell Rep. 2019 Aug 27;28(9):2331-2344.e8.|Cell Rep. 2019 Aug 27;28(9):2331-2344.e8.|Cell Syst. 2020 Nov 18;11(5):478-494.e9.|Commun Biol. 2020 Mar 17;3(1):128. |Exp Cell Res. 2022 Sep 21;113361.|Exp Mol Med. 2020 Jun;52(6):911-920.|Exp Ther Med. February 22, 2022.|FEBS Open Bio. 2020 Dec;10(12):2578-2587.|Front Immunol. 21 January 2021.|Hematol Oncol. 2023 Oct 24.|Hepatology. 2018 Jul;68(1):333-348.|Hepatology. 2020 Jul;72(1):155-168. |Inflamm Res. 2023 Jun 23.|J Biol Chem. 2024 Jul 30:107616.|J Exp Med. 2022 Apr 4;219(4):e20210739.|J Immunol Res. 2020 Jun 19;2020:4598476.|J Immunol. 2021 Sep 1;207(5):1419-1427.|J Magn Reson Imaging. 2024 Aug 27.|J Orthop Translat. 2022 Feb 17;32:112-120.|MedComm. 04 March 2022.|Microvasc Res. 2022 Jun 4;104397.|Mol Cell. 2021 Oct 7;81(19):4076-4090.e8.|Mol Med. 2024 Apr 9;30(1):47.|Nat Commun. 2019 Apr 1;10(1):1473. |Nat Commun. 2023 Apr 6;14(1):1933.|Nat Commun. 2018 Oct 30;9(1):4507. |Nat Immunol. 2021 Oct 22.|Neural Regen Res. 2025 Mar 1;20(3):858-872.|Neuro Oncol. 2019 Nov 4;21(11):1423-1435. |NPJ Precis Oncol. 2024 Jul 16;8(1):144.|Patent. US20190231805A1.|Patent. US20220380385A1.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Mar.|Sci Rep. 2023 Jun 20;13(1):10041.|Signal Transduct Target Ther. 2022 Sep 12;7(1):317.|SSRN. 2020 May.|Theranostics. 2021 Jan 1;11(2):555-566.|Thromb Res. 2023Jun 5.|Acta Pharm Sin B. 11 August 2021.|Cancer Discov. 2018 Oct;8(10):1237-1249. |Cancer Res Commun. 2023 Nov 30.|Cancer Res. 2020 Aug 15;80(16):3413-3423.|Inflammation. 2021 Feb 24.|Open Biol. 2017 May;7(5). pii: 170066.|Patent. US20200330595A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1801747-42-1